- Article
Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?
- Christoph Wetz,
- Julian Rogasch,
- Philipp Genseke,
- Imke Schatka,
- Christian Furth,
- Michael Kreissl,
- Henning Jann,
- Marino Venerito and
- Holger Amthauer
Background: in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET), the mTOR inhibitor everolimus is associated with significant improvement in progression-free survival (PFS). This study evaluated the lesional asphericity (ASP) in p...

